Cytotoxic therapy for @entity8 and XXXX : improved renal survival but high relapse rate.

@entity1 @entity1667 @entity8 @entity1985 @entity644 @entity263 @entity229 @entity786 @entity177 @entity281 @entity150 @entity1011 @entity230 @entity236 @entity454
BACKGROUND: @entity1 with @entity8 ( @entity8 ) and @entity177 have a high risk for progression to @entity454 ( @entity454 ). In the short term, treatment with oral @entity786 and @entity230 attenuates the deterioration of renal function in these @entity1 ; however, the long-term efficacy is unknown. METHODS: We have studied prospectively 65 @entity1 with @entity8 and @entity177 (serum @entity1011 >135 micromol/l) who were treated with oral @entity786 (1.5-2.0 mg/kg/day for 12 months) and @entity230 ( @entity1667 pulses 3 x 1 g, i.v. at months 1, 3 and 5, and oral @entity229 0.5 mg/kg/48 h for 6 months). RESULTS: Follow-up was 51 (5-132) months. Renal function temporarily improved or stabilized in all @entity1 . A partial remission (PR) occurred in 56 @entity1 followed by a complete remission (CR) in 17. During follow-up, 11 @entity1 had relapsed (28% relapse rate after 5 years), of whom nine were re-treated because of renal function deterioration. At the end of follow-up, 16 @entity1 were in CR, 31 in PR, eight had a persistent @entity1985 , one had mild @entity644 , four had progressed to @entity454 and five had died. Overall renal survival was 86% after 5 years and 74% after 7 years, compared with 32% after 5 and 7 years in a historical control group. Treatment-related complications occurred in two-thirds of @entity1 , mainly consisting of @entity236 and @entity281 . One @entity1 has developed @entity150 , another @entity1 @entity263 . CONCLUSIONS: Renal survival is good if @entity1 with @entity8 and @entity177 are treated with oral @entity786 . However, side effects occur frequently and relapse rate is high during longer follow-up.
